盆腔检查对疑似宫颈炎或盆腔炎性疾病年轻女性患者病史预测性传播感染的附加价值
这项前瞻性观察研究纳入城市学术儿科急诊科14至20岁、主诉阴道分泌物或下腹痛的女性患者,以尿检衣原体、淋球菌和滴虫为参考标准。执业者先按美国疾病控制与预防中心标准采集标准化病史并在100毫米视觉模拟量表上记录宫颈炎或盆腔炎性疾病的可能性,随后进行盆腔检查并再次记录可能性。288例中79例尿检阳性,性传播感染率27.4%(95%CI 22.6%至32.8%);仅病史敏感性54.4%(95%CI 42.8%至65.5%)、特异性59.8%(95%CI 52.8%至66.4%),病史加盆腔检查敏感性48.1%(95%CI 36.8%至59.5%)、特异性60.7%(95%CI 53.8%至67.3%)。盆腔检查信息改变处理71例,其中35例与性传播感染检测一致、36例不一致;作者认为盆腔检查的检验特征不充分,应重新考虑其常规实施。
要点
- 288例14至20岁疑似宫颈炎或盆腔炎性疾病女性中,尿检衣原体、淋球菌或滴虫阳性79例,性传播感染率27.4%(95%CI 22.6%至32.8%)。
- 仅病史诊断的敏感性54.4%(95%CI 42.8%至65.5%)、特异性59.8%(95%CI 52.8%至66.4%)。
- 病史加盆腔检查的敏感性48.1%(95%CI 36.8%至59.5%)、特异性60.7%(95%CI 53.8%至67.3%),未提高诊断准确性。
- 盆腔检查信息改变处理71例,其中35例与性传播感染检测一致、36例不一致。
- 作者认为盆腔检查的检验特征不充分,应重新考虑其常规实施。
适用人群与场景
- 14至20岁女性患者,主诉阴道分泌物或下腹痛,就诊于城市学术儿科急诊科。
诊断标准与关键阈值
- 执业者按美国疾病控制与预防中心标准采集标准化病史以评估宫颈炎或盆腔炎性疾病。
研究设计与关键结果
- 前瞻性观察研究,纳入288例14至20岁女性,79例尿检衣原体、淋球菌或滴虫阳性,性传播感染率27.4%(95%CI 22.6%至32.8%)。
- 仅病史诊断宫颈炎或盆腔炎性疾病的敏感性54.4%(95%CI 42.8%至65.5%)、特异性59.8%(95%CI 52.8%至66.4%)。
- 病史加盆腔检查的敏感性48.1%(95%CI 36.8%至59.5%)、特异性60.7%(95%CI 53.8%至67.3%)。
- 盆腔检查信息改变处理71例,其中35例与性传播感染检测一致、36例不一致。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于疑似宫颈炎或盆腔炎性疾病的年轻女性患者,盆腔检查未提高诊断衣原体、淋球菌或滴虫感染的敏感性或特异性,其常规实施应重新考虑。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: We evaluate the additive value of pelvic examinations in predicting sexually transmitted infection for young female patients with suspected cervicitis or pelvic inflammatory disease in a pediatric emergency department (ED).
METHODS: This was a prospective observational study of female patients aged 14 to 20 years who presented to an urban academic pediatric ED with a complaint of vaginal discharge or lower abdominal pain. Enrolled patients provided a urine sample for chlamydia, gonorrhea, and trichomonas testing, which served as the criterion standard for diagnosis. A practitioner (pediatric ED attending physician, emergency medicine or pediatric resident, pediatric ED fellow, or advanced practice provider) obtained a standardized history from the patient to assess for cervicitis or pelvic inflammatory disease according to the Centers for Disease Control and Prevention criteria. They then recorded the likelihood of cervicitis or pelvic inflammatory disease on a 100-mm visual analog scale. The same practitioner then performed a pelvic examination and again recorded the likelihood of cervicitis or pelvic inflammatory disease on a visual analog scale with this additional information. Using the results of the urine sexually transmitted infection tests, the practitioner calculated and compared the test characteristics of history alone and history with pelvic examination.
RESULTS: Two hundred eighty-eight patients were enrolled, of whom 79 had positive urine test results for chlamydia, gonorrhea, or trichomonas, with a sexually transmitted infection rate of 27.4% (95% confidence interval [CI] 22.6% to 32.8%). The sensitivity of history alone in diagnosis of cervicitis or pelvic inflammatory disease was 54.4% (95% CI 42.8% to 65.5%), whereas the specificity was 59.8% (95% CI 52.8% to 66.4%). The sensitivity of history with pelvic examination in diagnosis of cervicitis or pelvic inflammatory disease was 48.1% (95% CI 36.8% to 59.5%), whereas the specificity was 60.7% (95% CI 53.8% to 67.3%). The information from the pelvic examination changed management in 71 cases; 35 of those cases correlated with the sexually transmitted infection test and 36 did not.
CONCLUSION: For young female patients with suspected cervicitis or pelvic inflammatory disease, the pelvic examination does not increase the sensitivity or specificity of diagnosis of chlamydia, gonorrhea, or trichomonas compared with taking a history alone. Because the test characteristics for the pelvic examination are not adequate, its routine performance should be reconsidered.
参考来源
- Farrukh S, Sivitz AB, Onogul B, et al. The Additive Value of Pelvic Examinations to History in Predicting Sexually Transmitted Infections for Young Female Patients With Suspected Cervicitis or Pelvic Inflammatory Disease. Ann Emerg Med. 2018. PMID: 30251627. doi:10.1016/j.annemergmed.2018.05.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。